Effects of N-3 Polyunsaturated Fatty Acids on Left Ventricular Function and Functional Capacity in Patients With Dilated Cardiomyopathy

Nodari, Savina; Triggiani, Michele; Campia, Umberto; Manerba, Alessandra; Milesi, Giuseppe; Cesana, Bruno Mario; Gheorghiade, Mihai; Dei, Livio

doi:10.20996/1819-6446-2011-7-2-246-456

Cited by 28 publications

(37 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The recent GISSI-HF trial showed a modest but significant reduction in mortality with 1 g/d PUFA in patients with heart failure with reduced LVEF [72]. Similarly, another small study (n0133) demonstrated that patients with chronic heart failure due to nonischemic dilated cardiomyopathy who received 2 g of PUFAs for 12 months differed significantly from the placebo group (P<0.001) in regard to LVEF, peak oxygen consumption, exercise duration, and reduced hospitalization rates for heart failure [73]. Another recent study saw a dose-dependent response of PUFAs (1 g and 4 g) in patients with severe congestive heart failure, who had improved left ventricular function, endothelial function, and decreased inflammation after higher doses of PUFAs [74].…”

Section: Omega-3 Fatty Acidsmentioning

confidence: 99%

Pharmacologic Strategies to Target Oxidative Stress in Heart Failure

Ahmed

Tang

2012

Curr Heart Fail Rep

View full text Add to dashboard Cite

Reactive oxygen species (ROS), which are involved in normal physiological functions at low concentrations, can have deleterious effects when produced in excess. Over time, ROS may result in a pathological state of imbalance known as oxidative stress. Oxidative stress has long been implicated in many diseases, and is consistently associated with poor outcomes in heart failure. Most therapies that are currently being used may provide some reduction in oxidative stress, but there is no consensus on the clinical outcomes of various antioxidants. Currently, there are no antioxidant therapies that are being used routinely to specifically target oxidative stress in patients with heart failure. This article reviews the current understanding of ROS generation, and the potential for novel pharmacologic strategies to target oxidative stress in heart failure.

show abstract

Section: Omega-3 Fatty Acidsmentioning

confidence: 99%

Pharmacologic Strategies to Target Oxidative Stress in Heart Failure

Ahmed

Tang

2012

Curr Heart Fail Rep

View full text Add to dashboard Cite

show abstract

“…The intervention also resulted in lower re-hospitalization for HF vs. in placebo (6% vs. 30%, p=0.0002) [38].…”

Section: Discussionmentioning

confidence: 89%

Plasma Omega-3 Polyunsaturated Fatty Acids and Survival in Patients with Chronic Heart Failure and Major Depressive Disorder

Jiang

Oken²,

Fiuzat

et al. 2011

J. of Cardiovasc. Trans. Res.

View full text Add to dashboard Cite

The omega-3 fatty acid (FA) concentration is low in patients with coronary heart disease (CHD). Supplement of omega-3 FA improves cardiovascular outcomes in patients with CHD and heart failure (HF). However, plasma omega-3 FA and its role for prognosis in HF patients have not been examined previously. In this study, we explore the prognostic value of omega-3 polyunsaturated FA in HF patients with major depressive disorder (MDD). Plasma was obtained from HF patients with MDD who participated in the Sertraline Against Depression and Heart Disease in Chronic Heart Failure trial. FA methyl esters were analyzed by the method of a flame ionization detector. Weight percent is the unit of the omega compounds. The primary outcome was survival which was analyzed using Cox proportional hazards regression modeling. A total of 109 depressed HF patients had adequate volume for completion of the FA assays. Plasma total omega-3 (hazard ratio [HR] 0.65, 95% confidence interval [CI] 0.43-0.98) and EPA_(0.1 unit) (HR 0.73, 95% CI 0.56-0.96) were significantly associated with survival of patients with HF and co-morbid MDD. The results suggest that low plasma omega-3 FA is a significant factor for reduced survival in HF patients with MDD.

show abstract

“…Two small studies suggested a potential role for n-3 polyunsaturated fatty acids in nonischemic cardiomyopathy (52) and testosterone in elderly women with advanced HF (53). Coenzyme Q 10 , a cofactor in mitochondrial oxidative phosphorylation and generation of adenosine triphosphate, was not found to be an independent prognostic variable in HF, according to a pre-specified substudy of the CORONA (Controlled Rosuvastatin Multinational Study in Heart Failure) (54).…”

Section: Management Of Hfmentioning

confidence: 99%

The Year in Heart Failure

Owens

Jessup

2012

Journal of the American College of Cardiology

View full text Add to dashboard Cite

With health care reform and pay-for-performance measures in the near future, the heart failure (HF) community must critically appraise our practice patterns and processes of care. Ideally, our efforts begin with strategies to prevent HF, followed by therapies to treat HF and approaches to improving the cost-effectiveness of care. It is increasingly apparent that our current model is not sustainable, and we look to the scientists and clinicians in our field to provide innovative yet practical solutions. Herein, we discuss the major published clinical advances in HF over the past academicIn the United States, HF incidence approaches 10 per 1,000 population after 65 years of age (29). Efforts to prevent HF focus on the treatment of established risk factors and the development of risk scores to predict incident HF. One risk prediction score, the Health ABC Heart Failure Model, was validated externally in Cardiovascular Health Study participants, confirming the utility of 9 variables to predict incident HF. The strength of the model is its applicability to real-world practice, in which all of the variables are readily available (30). A separate study suggested that including only common cardiovascular risk factors (coronary disease, hypertension, diabetes, atrial fibrillation, valvular disease, and age) can predict incident HF in men and women during 1,015,794 person-years of follow-up (31). Lam et al. (32) showed that after adjustment for cardiac dysfunction, subclinical dysfunction in each noncardiac organ system was associated with a 30% increased risk for HF.Nevertheless, there is an unmet need to predict risk earlier. A small study by Yan et al. (33) reported the use of cardiac magnetic resonance imaging to detect subclinical, regional left ventricular (LV) dysfunction, as an independent predictor for incident HF and cardiovascular events in the asymptomatic, lower risk MESA (Multi-Ethnic Study of Atherosclerosis) cohort. Another investigation of an elderly cohort revealed an increased risk for LV diastolic dysfunction, independent of LV mass and traditional risk factors, that occurred with increased body mass index (34). These studies suggest that lifestyle counts in HF prevention efforts. Indeed, an analysis of almost 60,000 Finnish subjects free of HF at baseline showed that moderate and high levels of occupational and leisure-time physical activity were associated with a reduced risk for HF (35). BiomarkersThis year saw no new evidence that serial biomarker-guided management of HF could reduce morbidity or mortality. In both the STARBRITE (Strategies for Tailoring Advanced HF Regimens in the Outpatient Setting) and PRIMA (Can Pro-Brain-Natriuretic Peptide Guided Therapy of Chronic HF Improve HF Morbidity and Mortality) trials, the use of natriuretic peptide-guided therapy was associated with increased use of evidence-based medications but no improvement in days alive or decrease in HF hospitalizations (36,37).Several biomarker studies focused on predicting HF incidence in the community. Elevated cardiac tro...

show abstract

Effects of N-3 Polyunsaturated Fatty Acids on Left Ventricular Function and Functional Capacity in Patients With Dilated Cardiomyopathy

Cited by 28 publications

References 0 publications

Pharmacologic Strategies to Target Oxidative Stress in Heart Failure

Pharmacologic Strategies to Target Oxidative Stress in Heart Failure

Plasma Omega-3 Polyunsaturated Fatty Acids and Survival in Patients with Chronic Heart Failure and Major Depressive Disorder

The Year in Heart Failure

Contact Info

Product

Resources

About